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Abstract
IMPORTANCE Facioscapulohumeral muscular dystrophy (FSHD) is considered an autosomal
dominant disorder, associated with the deletion of tandemly arrayed D4Z4 repetitive elements. The
extensive use of molecular analysis of the D4Z4 locus for FSHD diagnosis has revealed wide clinical
variability, suggesting that subgroups of patients exist among carriers of the D4Z4 reduced
allele (DRA).
OBJECTIVE To investigate the clinical expression of FSHD in the genetic subgroup of carriers of a
DRAwith 7 to 8 repeat units (RUs).
DESIGN, SETTING, ANDPARTICIPANTS This multicenter cross-sectional study included 422
carriers of DRAwith 7 to 8 RUs (187 unrelated probands and 235 relatives) from a consecutive sample
of 280 probands and 306 relatives from the Italian National Registry for FSHD collected between
2008 and 2016. Participants were evaluated by the Italian Clinical Network for FSHD, and all clinical
and molecular data were collected in the Italian National Registry for FSHD database. Data analysis
was conducted from January 2017 to June 2018.
MAINOUTCOMES ANDMEASURES The phenotypic classification of probands and relatives was
obtained by applying the Comprehensive Clinical Evaluation Form which classifies patients in the 4
following categories: (1) participants presenting facial and scapular girdle muscle weakness typical of
FSHD (category A, subcategories A1-A3), (2) participants with muscle weakness limited to scapular
girdle or facial muscles (category B, subcategories B1 and B2), (3) asymptomatic or healthy
participants (category C, subcategories C1 and C2), and (4) participants with myopathic phenotypes
presenting clinical features not consistent with FSHD canonical phenotype (category D,
subcategories D1 and D2).
RESULTS A total of 187 probands (mean [SD] age at last neurological examination, 53.5 [15.2] years;
103 [55.1%]men) and 235 relatives (mean [SD] age at last neurologic examination, 45.1 [17.0] years;
104 [44.7%]men) with a DRAwith 7 to 8 RUs and amolecular diagnosis of FSHDwere evaluated. Of
187 probands, 99 (52.9%; 95% CI, 45.7%-60.1%) displayed the classic FSHD phenotype, whereas
86 (47.1%; 95% CI, 39.8%-54.3%) presented incomplete or atypical phenotypes. Of 235 carrier
relatives from 106 unrelated families, 124 (52.8%; 95% CI, 46.4%-59.7%) had nomotor impairment,
whereas a small number (38 [16.2%; 95% CI, 9.8%-23.1%]) displayed the classic FSHD phenotype,
and 73 (31.0%; 95% CI, 24.7%-38.0%) presented with incomplete or atypical phenotypes. In 37 of
106 families (34.9%; 95% CI, 25.9%-44.8%), the proband was the only participant presenting with a
myopathic phenotype, while only 20 families (18.9%; 95% CI, 11.9%-27.6%) had amember with
autosomal dominant FSHD.
(continued)
Key Points
Question What are the phenotypes
expressed among patients with
facioscapulohumeral muscular
dystrophy (FHSD) who are carriers of
D4Z4 reduced allele with 7 to 8
repeat units?
Findings In this cross-sectional study of
187 probands and 235 relatives who
carry a D4Z4 reduced allele with 7 to 8
repeat units, 47.1% of probands did not
have the classic FSHD phenotype, and
52.8% of the carrier relatives were
nonpenetrant. In 106 families, 18.9%
had amemberwith autosomal dominant
FSHD, whereas in 34.9%, the proband
was the only participant expressing a
myopathic phenotype.
Meaning The findings of this study
suggest that knowledge of phenotypic
variation in the expression of D4Z4
reduced allele with 7 to 8 repeat units in
individuals with FSHD could be
informative for clinical management and
genetic counseling.
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE This study found large phenotypic variability associated with
individuals carrying a DRAwith 7 to 8 RUs, in contrast to the indication that a positive molecular test
is the only determining aspect for FSHDdiagnosis. These findings suggest that carriers of a DRAwith
7 to 8 RUs constitute a genetic subgroup different from classic FSHD. Based on these results, it is
recommended that clinicians use the Comprehensive Clinical Evaluation Form for clinical
classification and, whenever possible, study the extended family to provide themost adequate
clinical management and genetic counseling.
JAMA Network Open. 2020;3(5):e204040. doi:10.1001/jamanetworkopen.2020.4040
Introduction
Facioscapulohumeral muscular dystrophy (FSHD; OMIM 158900) is among themost common forms
of hereditary myopathy.1 At present, 2 genetically distinct disease subtypes, FSHD1 and FSHD2, are
described2,3 on the basis of molecular features. In FSHD1, representative of 95% of patients, the
molecular variation resides in a stretch of tandemly arrayed 3.3-kb repetitive elements named D4Z4.
Patients with FSHD1 carry D4Z4 alleles with 10 or fewer repeat units (RUs), with autosomal dominant
inheritance.4 In FSHD2, individuals carry 2 D4Z4 arrays in the healthy range (ie, >10 RUs), but
approximately 80%of these patients have amutation in the SMCHD1 gene (OMIM614982) with D4Z4
reduced CpGmethylation and a permissive 4qA haplotype. It has to be noted that SMCHD1 variants
as well as D4Z4 hypomethylation in the presence of the haplotype 4qA/PAS distal to the D4Z4 array
have been found in patientswith bosma arhinia andmicrophtalmia syndrome, a congenital diseasewith
no associatedmuscle phenotype.5-12
The classic FSHD phenotype is characterized by onset in the first or second decade of life with
progressive facial, shoulder girdle, and pectoral muscle weakness and atrophy, often asymmetric.13
Disease progression may lead to the involvement of abdominal muscles and distal lower extremity
weakness, causing a steppage gait before impairment of pelvic girdle muscles.14
Patients with the smallest number of RUs display more severe phenotypes, including earlier
wheelchair use and increased frequency of extramuscular manifestations.15 In contrast, patients with
the largest number of residual D4Z4 fragments (ie, 7-10 RUs) have amilder disease and no affected
relatives.16
However, since its discovery, molecular analysis of the D4Z4 locus for FSHD diagnosis has
revealed an unanticipated complexity, without a straightforward association of the clinical
phenotype with molecular variations.17 Furthermore, the autosomal dominant mode of inheritance
has come into question because there are families in which the disease appears only in 1 generation
or in a single individual.18-23 Several reports describe atypical phenotypes in carriers of D4Z4 reduced
alleles (DRAs).24 In some of these cases, additional investigations revealed the presence of variants
in neuromuscular disorder genes that can explain the atypical clinicaphenotypes.25-41 Moreover,
D4Z4 alleles in the range of FSHD1 (ie, 4-8 RUs) are carried by 3% of the healthy population.5,19,20We
also found that 1.3%of healthy people carry 1 DRA associatedwith the permissive haplotype 1614qA,
and 2% carry 1 DRA with the 4qA allele.5 These observations argue for the role of modifying loci or
epigenetic mechanisms influencing the clinical expression of disease.42
In the present study, we applied the Comprehensive Clinical Evaluation Form (CCEF), a clinical
tool developed to systematically describe clinical phenotypes in individuals with suspected FSHD,
with the aim of obtaining additional information about the clinical significance of detecting a DRA
with 7 to 8 RUs. These alleles have a 2 in 10 frequency (eFigure 1 in the Supplement) in the population
accrued in the Italian National Registry for FSHD (INRF) and 1.7% in the general population5;
therefore, their detection has high clinical relevance but requires additional knowledge to establish
their value for diagnosis and genetic counseling. At present, a standardized genotype-phenotype
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correlation analysis of probands and relatives does not exist for carriers of a DRAwith 7 to 8 RUs.43-47
Here we evaluate whether this genetic subgroup is different from those with classic FSHD.
Methods
StudyDesign and Participants
We performed a cross-sectional study of 187 probands (ie, the family member who first manifested
symptoms and was the first individual analyzed) and 235 relatives from a consecutive group of 280
probands and 306 relatives, all carriers of a DRAwith 7 to 8 RUs, accrued by the INRF between 2008
and 2016. All participants included in this study carry 1 DRA associatedwith the permissive haplotype
4qA. We did not analyze the short sequence-length polymorphism in all participants, given that
several studies have shown that different haplotypes can be carried by patients with FSHD.5-12 The
carriers of DRA with 7 to 8 RUs represent 20% of all carriers accrued by INRF (eFigure 1 in the
Supplement). We enrolled only patients for whom clinical evaluation was performedwith the CCEF
by a properly trained physician who belonged to the Italian Clinical Network for FSHD (ICNF). The
ICNF is distributed across Italy and includes 1 diagnostic laboratory and 14 clinical centers. All clinical
and molecular data were collected in the INRF database. Participant recruitment was approved by
the Ethics Committee of Modena and all participating centers. Written informed consent, according
to the Declaration of Helsinki, was obtained from each participant enrolled in the study. This study
followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline for cross-sectional studies.
Procedures
Clinical Investigation
We applied the CCEF, a recently published48 novel clinical standardized clinical tool with interrater
reliability.48 The CCEF consists of 4 sections. The first section, the evaluation form, investigates the
patient’s clinical history and disability and assesses muscle segmental involvement. The second
section includes the FSHD evaluation scale to calculate the FSHD score (range, 0-15).49 The
combination of the clinical features summarized in the clinical diagnostic form (section 3) assigns
patients to different phenotypic categories (section 4). Participants presenting with facial and
scapular girdle muscle weakness typical of FSHD are classified as category A, subcategories A1 to A3;
those with muscle weakness limited to scapular girdle or facial muscles are assigned to category B,
subcategories B1 and B2, respectively; those who are asymptomatic or healthy are assigned to
category C, subcategories C1 and C2; and those with myopathic phenotypes presenting clinical
features not consistent with the FSHD canonical phenotype are assigned to category D,
subcategories D1 and D2.
Molecular Characterization
As previously described,15 allele sizes were estimated by Southern hybridization with probe p13E-11
of 7 μg of EcoRI-digested, EcoRI/BlnI-digested genomic DNA extracted from peripheral blood
lymphocytes, electrophoresed in a 0.4% agarose gel, for 45 to 48 hours at 35 V, alongside an 8- to
48-kb marker (BioRad). Participants carrying DRA with 7 to 8 RUs were included in the study. To
distinguish between DRAs from chromosome 10q and 4q, DNA from each proband was analyzed by
NotI digestion and hybridizationwith the B31 probe to confirm the chromosome4q origin of the 33-
to 35-kb EcoRI allele. Restriction fragments were detected by autoradiography or by using the
Typhoon Trio system (GE Health).
Statistical Analysis
Numerical variables were described using mean (SD) and compared between groups using 1-way
analysis of variance, followed by Tukey honest significance post hoc test, in cases of more than 2
groups, or the t test for independent samples, in cases of 2-group comparisons. Linear models were
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used to adjust comparisons with respect to potential confounding factors. Categorical variables were
synthetized using absolute frequencies with percentages, and differences in distribution were
assessed using the χ2 test. We obtained 95% CIs on proportions using the exact method for binomial
andmultinomial proportions. Missing values were not imputed. All reported P values were 2-sided,
and statistical significance was set at a P < .05. All statistical analyses were performedwith R version
3.5.0 (R Project for Statistical Computing).
Results
We reevaluated 187 unrelated probands (mean [SD] age at last neurological examination, 53.5 [15.2]
years). In the 103men (55.1%), themean (SD) age was 49.9 (15.5) years; in the 84women (44.9%),
it was 57.9 (13.6) years (P < .001). We identified 235 related carriers of DRAwith 7 to 8 RUs from 106
unrelated families. The number of relatives tested in each family was variable, with a range of 1 to 10
members, with a mean (SD) of 2.2 (1.6) relatives for each family. Among family members, mean (SD)
age at last neurological examination was 45.1 (17.0) years; in the 104men (44.7%), it was 39.4 (15.1)
years, and in the 131 women (55.3%), it was 49.5 (17.2) years (P < .001) (Table).
Distribution of Clinical Categories Among Probands
We grouped the probands in clinical categories on the basis of their clinical phenotype (Figure 1A):
99 (52.9%; 95% CI, 45.7%-60.1%) displayed the classic FSHD phenotype, and were classified as
category A, whereas 86 (47.1%; 95% CI, 39.8%-54.3%) presented incomplete or atypical
Table. Clinical Summary of Probands and Relatives
Characteristic
Probands Relatives
All (n = 187) Men (n = 103) Women (n = 84) P value All (n = 235) Men (n = 104) Women (n = 131) P value
Age at evaluation, mean (SD), y 53.5 (15.2) 49.9 (15.5) 57.9 (13.6) <.001 45.1 (17.0) 39.4 (15.1) 49.5 (17.2) <.001
Age at onset, mean (SD), y 33.3 (17.9) 28.8 (16.2) 39.1 (18.3) <.001 33.4 (17.3)a 25.7 (12.3)a 38.8 (18.4)a <.001
FSHD score, mean (SD), y 5.8 (3.4) 5.7 (3.5) 6.0 (3.2) .66 3.6 (3.0)a 3.2 (2.6)a 3.9 (3.2)a .25
Abbreviation: FSHD, facioscapulohumeral muscular dystrophy.
a Calculated with 107 relatives (46men; 61 women) with FSHD symptoms.
Figure 1. Description of Clinical Phenotypes Observed Among Probands and Relatives
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Category A includes patients with typical facioscapulohumeral muscular dystrophy,
presenting facial and scapular girdle muscle weakness without atypical features. Patients
with this typical phenotype are further subdivided in 3 subcategories (A1-A3). Category
B includes patients with muscle weakness limited to scapular girdle (B1) or facial (B2)
muscles. Category C includes asymptomatic individuals without motor impairment. This
group is further divided in 2 subcategories, as follows: C1, patient with minor signs; and
C2, patients with completely normal results from a neurologic examination. Category D
comprises atypical phenotypes. In particular, those assessed as category D1 present
some facioscapulohumeral muscular dystrophy features with other uncommon
characteristics suggestive of the possible copresence of an additional muscle disease.
Patients in category D2 do not fulfil the diagnostic criteria for facioscapulohumeral
muscular dystrophy.
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phenotypes, with 36 (19.3%; 95% CI, 14.0%-25.8%) displaying incomplete FSHD phenotype
(category B), 33 (17.6%; 95% CI, 12.6%-24.0%) presenting shoulder involvement without facial
weakness (category B1), and 50 (26.7%; 95% CI, 20.7%-33.8%) with atypical clinical features not
consistent with classic FSHD (category D). We observed a significantly different distribution of
gender across clinical categories (P = .002) (Figure 2). In particular, the number of men (24 [72.7%;
95% CI, 54.2%-86.1%]) showing a facial-sparing phenotype (category B1) was higher compared with
women (9 [27.3%; 95%CI, 13.9%-45.8%]), whereas the atypical phenotypes (category D)weremore
frequent in women thanmen (33 [66.0%; 95% CI, 51.1%-78.4%] vs 17 [34.0%; 21.6%-48.9%]). Age
at last clinical evaluation was significantly different among categories with patients in category D
being older (mean [SD] age, 59.0 [13.7] years) than those with classic (mean [SD] age, 52.2 [15.1]
years; P = .007) or incomplete (mean [SD] age, 50.1 [15.7] years; P = .009; P for analysis of
variance = .01) FSHD phenotypes.
Distribution of Clinical Categories AmongRelatives
Clinical evaluation of 235 relatives (Figure 1B) showed that 38 (16.2%; 95%CI, 9.8%-23.1%) displayed
the classic FSHD phenotype (category A), and 124 (52.8%; 95% CI, 46.4%-59.7%) had nomuscle
weakness (category C). A total of 73 relatives (31.0%; 95% CI, 24.7%-38.0%) presented with
incomplete or atypical phenotypes, with 51 (21.7%; 95% CI, 16.7%-27.6%) with an incomplete FSHD
phenotype (category B), 14 (5.9%; 95% CI, 3.4%-10.0%) with uncommon characteristics suggestive
of a possible comorbidity (category D1), and 8 (3.4%; 95% CI, 1.6%-6.8%) with clinical features not
consistent with FSHD (category D2). No differences were observed across categories of relatives
with respect to sex (P = .09).
Distribution of Clinical Categories in Families
Facioscapulohumeral muscular dystrophy is characterized by great variability in clinical expression.
To investigate this aspect, we grouped families based on the proband’s clinical category and
subgrouped them based on the clinical patterns assessed in relatives (Figure 3; eFigure 2 in the
Supplement). Among all families with the proband assessed as category A, we found that 30 relatives
(22.4%; 95%CI, 15.8%-30.6%) were assessed as category A. Only in 10.0% (95%CI, 4.1%-21.2%) of
families (6 of 60) did all relatives display the classic FSHD phenotype. In contrast, 39 families (65.0%;
95% CI, 51.5%-76.6%) had at least 1 nonpenetrant carrier, and in 19 families (31.7%; 95% CI,
20.6%-45.1%), all relatives carrying 1 DRAwere nonpenetrant. Whenwe considered families with the
proband classified as category B, 10 relatives (30.3%; 95% CI, 16/2%-48.9%) were assessed as
category B, whereas 16 (48.5%; 95% CI, 31.2%-66.1%) were nonpenetrant carriers. Considering
families with the proband classified as category D, 40 relatives (67.8%; 95% CI, 54.2%-79.0%) were
nonpenetrant carriers (eTable 1 in the Supplement). Finally, in one-third of families (37 [34.9%; 95%
CI, 25.9%-44.8%]), the proband was the only participant who presented a myopathic phenotype,
Figure 2. Distribution of Sex Across Clinical Category
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while only 20 families (18.9%; 95% CI, 11.9%-27.0%) had amember with an autosomal dominant
FSHD. The percentages of relatives with classic FSHD phenotype in families with the proband
classified as category B and Dwere 6.1% (2 relatives) and 8.5% (5 relatives), respectively.
Age at Onset
Themean (SD) age at onset estimated among probands was 33.3 (17.9) years, and 124 (66.3%)
presented with first symptoms when older than 20 years. Mean (SD) age at onset was significantly
different betweenmen andwomen (28.8 [16.2] vs 39.1 [18.3]; P < .001) (eTable 2 in the Supplement).
Age at onset of probands was also different across categories, with participants with classic FSHD
phenotypes (ie, category A) having significantly earlier onset than thosewith atypical phenotypes (ie,
category D) (mean [SD] age, 29.1 [16.4] vs 40.9 [17.8] years; P = .001; P for analysis of
variance < .001).We found the same pattern of difference inmean (SD) age of onset in relatives (men
vs women: 25.7 [12.3] years vs 38.8 [18.4] years; P = .001; category A vs D: 29.2 [17.6] years vs 43.6
[18.0] years; P = .02). The mean (SD) age at onset of symptomatic relatives (33.4 [17.3] years) was
lower than themean (SD) age at last neurological examination of relatives with nomuscle weakness
(ie, category C; 41.1 [15.3] years) (eTable 2 in the Supplement).
At onset, 178 of 246 patients (72.4%) reported scapular girdle weakness, 13 of 246 (5.3%)
referred to signs of facial weakness, and 31 (12.2%) presented with pelvic girdle weakness. In the
latter group, 24 of 31 (77.4%) were women.
Severity ofMotor Impairment
We also established the degree of motor impairment among probands using the FSHD clinical score
(Figure 4). The mean (SD) FSHD score was 5.8 (3.4). We did not detect a significant difference in
FSHD score betweenmen and women (5.7 [3.5] vs 6.0 [3.2]; P = .66). Instead, we detected a
difference in FSHD score among probands and symptomatic relatives, with the latter presenting less
severe clinical impairment (mean [SD] FSHD score, 5.8 [3.4] vs 3.6 [3.6]; P < .001).
Our analysis also revealed that participants assessed as category A developed amore severe
disease than subjects assessed as category B (mean [SD] FSHD score, 6.7 [3.3] vs 3.1 [1.6]; P < .001).
This difference remained significant even after adjusting the comparison by age at onset and disease
duration (difference in FSHD score, 3.2; 95%CI, 2.1-4.3; P < .001).We found no significant difference
in FSHD score between participants classified as category A and those classified as category D, even
though the muscles affected in the 2 subgroups are different. In particular, facial weakness
significantly contributed to the whole FSHD score in subjects assessed as category A compared with
those in category D (mean [SD] contribution, 25.0% [12.8%] vs 16.4% [20.0%]; P = .006), whereas
Figure 3. Distribution of Clinical Categories Of Relatives in RelationshipWith the Clinical Category of Probands
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Only probands with at least 1 family member available for the analysis (106 of 187 [56.7%]) were included.
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limb girdle muscles significantly contributed to the whole FSHD score in those assessed as category
D compared with those assessed as category A (mean [SD] contribution of impairment of limb girdle
muscles: 29.4% [17.9%] vs 13.2% [14.9%]; P < .001). This estimate was achieved evaluating the
contribution of each subscore to the whole score.
Discussion
In FSHD genotype-phenotype correlation studies, the idea that there is an inverse correlation
between the number of D4Z4 repeats and the severity of the disease has been favored.43 Alleles with
DRAwith 1 to 3 RUs were generally associated with amore severe form of disease, while DRAwith 4
to 8 RUs was associated with the classic form of FSHD.15,16 However, it is now clear that many
different phenotypes can be observed among individuals carrying a DRA, even DRAs of the same
size, with critical consequences for clinical management.24
The recently published evidence-based guidelines for the diagnosis andmanagement of
FSHD50 proposed that molecular testing, including themeasurement of the size of D4Z4 alleles, the
presence of 4qA polymorphism, and the D4Z4methylation status, become a determinant aspect
for diagnosis, whereas clinical features are not taken into account. In this study, we showed that
among carriers with DRAwith 7 to 8 RUs, themolecular test was not sufficient for diagnosis.
Considering the phenotypic variability of the probands and the high percentage of nonpenetrant
individuals among relatives, finding a D4Z4 contractionmight have little diagnostic and prognostic
significance. We suggest applying the CCEF as a tool for the standard evaluation of the phenotype in
conjunctionwith themolecular test. Our study showed that it ismandatory to extend themolecular
test to the largest number of family members for proper genetic counselling.
Our analysis of 422 participants also provided elements for managing diagnosis, prognosis, and
counseling among carriers of DRAwith 7 to 8 RUs.We showed that thismolecular group constitutes
a very heterogeneous clinical group, including phenotypes different from the classic form of FSHD.
We observed that 52.9% of probands had the classic FSHD phenotype (ie, category A in the CCEF),
whereas the rest (47.1%) displayed incomplete or atypical phenotypes. Among 187 probands, very
few (4.2%) had severe facial involvement (category A1). This is a peculiar clinical aspect; in fact, we
have shown previously that the percentage of patients with a classical phenotype in the carriers of
smaller DRAs was close to 80% among carriers of DRA with 1 to 3 RUs.15 In addition, the percentage
of relatives who are asymptomatic carriers was lower, ranging from 9.5% (for DRA with 1-3RUs) to
27.6% (for DRA with 4-6 RUs).18 Instead, the phenotypic expression of probands and relatives who
Figure 4. Severity ofMuscle Impairment In Probands and Relatives
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Degree of motor impairment, measured as facioscapulohumeral muscular dystrophy score, is described on the basis of age at last clinical evaluation and clinical category in probands
(A) and relatives (B).
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carry 1 DRAwith 7 to 8 RUs is quite similar to those with 9 to 10 RUs (G. Ricci, PhD, unpublished data,
2020). Therefore, the group with DRAwith 7 to 8 RUs is not a classic FSHD group, as suggested by
the FSHD guidelines. Instead, the characteristics are more similar to those found in carriers of
borderline alleles. At onset, most participants (71.9%) reported scapular girdle weakness, and 17.6%
presentedwith a facial-sparing phenotype (ie, category B1). Thus, in patients with a DRAwith 7 to 8
RUs, facial involvementwas less frequent and less severe than previously reported among individuals
carrying DRAwith fewer RUs.15 In our cohort, most symptomatic patients reported the first symptom
when theywere older than 20 years, without a statistically significant difference between themean
of age at onset for probands and relatives. Therefore, we can consider carriers of a DRA with 7 to 8
RUs as late-onset patients.51
This observation is also very interesting from another point of view. In our cohort, we reported
several families with relatives in 3 generations, and the absence of statistically significant difference
between the mean age at onset for probands and relatives suggests that no anticipation was
detectable in our sample.
Among probands, 26.7% displayed atypical signs (ie, category D) and showed some distinctive
features. First, patients in category D reported disease onset at older than 40 years. Therefore, we
can consider them late-onset patients. Second, no probands assigned to category D displayed
autosomal dominant inheritance; rather, they were sporadic cases. In this subgroup, most patients
presented with some FSHD features as well as other uncommon characteristics suggestive of the
possible copresence of an additional disease (ie, subcategory D1). In addition, 3.7% of these patients
presented no signs that met the diagnostic criteria for FSHD (ie, subcategory D2). Considering that
3% of general population5 carry a DRAwith 4 to 8 RUs, some patients in category D2 have a different
myopathy, and the association with the DRAwith 7 to 8 RUsmight be attributed to random
occurrence. To our knowledge, this was the first study in which a large group of myopathic carriers of
themolecular defect associated with FSHD1 was identified. These patients did not meet the clinical
criteria, and they indicate alternative diagnoses. The next step is to performmuscle biopsies and
exome sequencing to identify other causative genes in this subgroup of patients.
The evaluation of the FSHD clinical score confirms that myopathic carriers of 1 DRAwith 7 to 8
RUs had a mild clinical impairment,16,18,52 but at the same time, we observed large variability of
clinical expression, particularly among probands. Family studies show that this variability does not
depend exclusively on disease duration. We also found that most relatives (52.8%) carrying a DRA
with 7 to 8 RUs had no muscle weakness. This percentage is much higher than the 25% to 30%
reported by other studies.18,23,52 This difference is not because of the age at last clinical evaluation,
given that asymptomatic and nonpenetrant relatives in our cohort were older than the mean age at
onset of symptomatic relatives. Thus, it is likely that they will never develop disease.
In 34.9% of families, all relatives were healthy, irrespective of the proband’s clinical category.
This observation shows that disease penetrance varied among families and indicates that the genetic
background or the presence of comorbidities might modulate disease onset and development. Our
data point at the possibility that, in the heterozygous state, a D4Z4 reduction might produce a
subclinical, sensitized condition that requires another contributing factor to cause overt myopathy.
In some cases, it might be the simultaneous heterozygosity for a different and recessivemyopathy, as
suggested bymany reports, in which the FSHD contractions are found in association with a second
molecular variation.25-41 This possibility is also consistent with previous reports of expression
changes of candidate proteins that were associated with FSHD in some families but were unchanged
when other families were examined. It is also plausible that drugs or toxic agents might contribute
to disease onset and clinical variability. In this respect, anamnestic records documented by the CCEF
may provide useful information. Consequently, an extended evaluation of the family context is
necessary to estimate prognosis for patients carrying or at risk of carrying DRAwith 7 to 8 RUs.
Finally, by evaluating age at onset in combination with FSHD score and clinical category, we
found that women had a later onset and frequently display atypical phenotypes. It is commonly
reported that women have amilder phenotype, but the reasons are not well known.53 Our data
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suggest the role of sex-specific factors that delay disease onset in women or accelerate or facilitate
disease appearance in men. Considering the mean age at onset in woman, we can hypothesize a
crucial role of hormonal factors related to fertile age, but this hypothesis should be confirmed by
dedicated studies. It is also possible that factors expressed bymen (eg, testosterone is a potent
anabolic factor promotingmuscle protein synthesis andmuscular regeneration) create a major
sensitivity to the alterations caused by the FSHD pathogenic mechanism amongmen.54 Moreover,
men and women may respond differently to catabolic conditions because of their hormonal
profiles.55,56
Limitations
This study has some limitations. The CCEF is an extensive clinical tool, which takes about 20minutes
to apply. Only a physician with expertise in neuromuscular disease can use the tool correctly. Thus,
it is preferable they be properly trained. Second, a long follow-up period may be necessary to
evaluate whether some symptomatic patients will be assigned to a different clinical category or if
some nonpenetrant relatives will develop any sign of muscle impairment.
Third, most nonpenetrant relatives were older than 20 years, and themean (SD) of age at last
neurological examination (ie, 41.1 [15.3] years) was older than that of symptomatic relatives (ie, 33.4
[17.3] years). Thus, it is likely that they will never develop disease or that they might develop some
symptoms at older age. In our cohort we had several patients with atypical phenotypes who
developed the disease when older than 40 years. The clinical follow-up of nonpenetrant subjects will
provide relevant clinical information on this matter.
Conclusions
The findings of this study indicate that in the case of probands who carry a DRAwith 7 to 8 RUs and
do not present the classic FSHD phenotype, it is necessary to consider alternative myopathies. In
sporadic cases presenting with atypical phenotypes, the random association of a myopathic
phenotype with a contracted D4Z4 allele has to be considered, given that there is a 1.7% frequency
of DRAwith 7 to 8 RUs in the general population. This study showed that the genetic background can
influence the penetrance and phenotypic expression of disease in relatives carrying the same
molecular signature. Based on the results of our study, the precise phenotypic characterization of
patients and families should support molecular testing and could advance themanagement of
diagnosis, genetic counseling, and selection procedures for randomized clinical trials.
ARTICLE INFORMATION
Accepted for Publication:March 3, 2020.
Published:May 1, 2020. doi:10.1001/jamanetworkopen.2020.4040
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Ruggiero L
et al. JAMA Network Open.
Corresponding Author: Rossella Tupler, PhD, Department of Life Sciences, University of Modena and Reggio
Emilia, via G. Campi 287, Modena, Italy 41125 (rossella.tupler@unimore.it).
Author Affiliations:Department of Neurosciences, Reproductive, and Odontostomatological Sciences, University
Federico II, Naples, Italy (Ruggiero, Manganelli, Santoro); Department of Life Sciences, University of Modena and
Reggio Emilia, Modena, Italy (Mele, Ricci, Govi, Vallarola, Tomelleri, Tupler); Department of Preventive Medical
Sciences, Federico II University, Naples, Italy (Bruzzese); Neurological Clinic, Department of Clinical and
Experimental Medicine, University of Pisa, Italy (Ricci, Siciliano); Center for Neuromuscular Diseases, Department
of Neurosciences, University of Turin, Turin, Italy (Vercelli, Mongini); Department of Neurosciences, University of
Padua, Padua, Italy (Tripodi, Pegoraro); Neuromuscular Unit, Fondazione IRCCS Ca’Granda Ospedale Maggiore
Policlinico, Dino Ferrari Center, University of Milan, Milan, Italy (Villa, Moggio); Center for Neuromuscular Disease,
Center for Excellence on Aging, Gabrile D’Annunzio University Foundation, Chieti, Italy (DiMuzio); Neuromuscular
JAMANetworkOpen | Neurology Phenotypic Variability Among Patients With D4Z4 Reduced Allele FSHD
JAMA Network Open. 2020;3(5):e204040. doi:10.1001/jamanetworkopen.2020.4040 (Reprinted) May 1, 2020 9/13
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 06/17/2020
Repair Unit, Inspe and Division of Neuroscience, IRCSS San Raffaele Scientific Institute, Milan, Italy (Scarlato,
Previtali); Department of Neuroscience, Mental Health, and Sensory Organs, S. Andrea Hospital, University of
Rome Sapienza, Rome, Italy (Bucci, Antonini); IRCCS Foundation, C. Besta Neurological Institute, Milan, Italy
(Maggi); Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy (Rodolico);
Neurology Clinic, Spedali Civili Hospital, Brescia, Italy (Filosto); IRCCS San Camillo, Venezia, Italy (Angelini); Child
Neurology and Psychiatry Unit, IRCCS, Casimiro Mondino Foundation, Pavia, Italy (Berardinelli); Department of
Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester (Tupler); Li Weibo
Institute for Rare Diseases Research at the University of Massachusetts Medical School, Worcester (Tupler).
Author Contributions:Dr Tupler had full access to all of the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis.
Concept and design: Ruggiero, Mele, Ricci, Vercelli, Bucci, Rodolico, Angelini, Moggio, Siciliano, Santoro, Tupler.
Acquisition, analysis, or interpretation of data: Ruggiero, Mele, Manganelli, Bruzzese, Ricci, Vercelli, Govi, Vallarola,
Tripodi, Villa, Di Muzio, Scarlato, Bucci, Antonini, Maggi, Tomelleri, Filosto, Previtali, Berardinelli, Pegoraro,
Mongini, Siciliano, Tupler.
Drafting of the manuscript: Ruggiero, Mele, Bruzzese, Govi, Tripodi, Bucci, Tupler.
Critical revision of the manuscript for important intellectual content: Ruggiero, Manganelli, Ricci, Vercelli, Vallarola,
Villa, Di Muzio, Scarlato, Bucci, Antonini, Maggi, Rodolico, Tomelleri, Filosto, Previtali, Angelini, Berardinelli,
Pegoraro, Moggio, Mongini, Siciliano, Santoro, Tupler.
Statistical analysis: Bruzzese, Vallarola, Tupler.
Obtained funding: Bucci, Angelini, Tupler.
Administrative, technical, or material support:Mele, Govi, Bucci, Previtali, Tupler.
Supervision: Ruggiero, Ricci, Vercelli, Scarlato, Bucci, Rodolico, Filosto, Berardinelli, Mongini, Santoro, Tupler.
Conflict of Interest Disclosures: Dr Maggi reported receiving travel, congress, and speaking fees from Sanofi-
Genzyme and Biogen outside the submitted work. Dr Pegoraro reported receiving grants from Santhera, personal
fees from Sarepta, nonfinancial support from Genzyme, and nonfinancial support and personal fees from PTC
Pharmaceuticals and Biogen outside the submitted work. No other disclosures were reported.
Funding/Support: The Telethon Italy Foundation supported the creation of Italian National Registry for
Facioscapulohumeral Muscular Dystrophy and the Italian Clinical Network for Facioscapulohumeral Muscular
Dystrophy with grants GUP13012E and GUP11009. Dr Tupler was supported by grants from Regione Emilia
Romagna, Italy.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; preparation, review, or approval of themanuscript; and
decision to submit themanuscript for publication.
Meeting Presentation: This study was presented at 26th Annual Facioscapulohumeral Muscular Dystrophy
International Research Congress of the Facioscapulohumeral Society; June 20, 2019; Marseille, France.
REFERENCES
1. Deenen JC, Arnts H, van der Maarel SM, et al. Population-based incidence and prevalence of
facioscapulohumeral dystrophy. Neurology. 2014;83(12):1056-1059. doi:10.1212/WNL.0000000000000797
2. Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future
directions. Curr Opin Neurol. 2011;24(5):423-428.
3. de Greef JC, Lemmers RJ, Camaño P, et al. Clinical features of facioscapulohumeral muscular dystrophy 2.
Neurology. 2010;75(17):1548-1554. doi:10.1212/WNL.0b013e3181f96175
4. Wijmenga C, Hewitt JE, Sandkuijl LA, et al. Chromosome 4q DNA rearrangements associated with
facioscapulohumeral muscular dystrophy. Nat Genet. 1992;2(1):26-30. doi:10.1038/ng0992-26
5. Scionti I, Greco F, Ricci G, et al. Large-scale population analysis challenges the current criteria for themolecular
diagnosis of facioscapulohumeral muscular dystrophy. Am J HumGenet. 2012;90(4):628-635. doi:10.1016/j.ajhg.
2012.02.019
6. Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an SMCHD1mutation and an FSHD-permissiveD4Z4
allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet. 2012;44(12):1370-1374. doi:10.1038/
ng.2454
7. Sacconi S, Lemmers RJLF, Balog J, et al. The FSHD2 gene SMCHD1 is a modifier of disease severity in families
affected by FSHD1. Am J HumGenet. 2013;93(4):744-751. doi:10.1016/j.ajhg.2013.08.004
8. LarsenM, Rost S, El Hajj N, et al. Diagnostic approach for FSHD revisited: SMCHD1mutations cause FSHD2 and
act as modifiers of disease severity in FSHD1. Eur J Hum Genet. 2015;23(6):808-816. doi:10.1038/ejhg.2014.191
JAMANetworkOpen | Neurology Phenotypic Variability Among Patients With D4Z4 Reduced Allele FSHD
JAMA Network Open. 2020;3(5):e204040. doi:10.1001/jamanetworkopen.2020.4040 (Reprinted) May 1, 2020 10/13
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 06/17/2020
9. Gurzau AD, Chen K, Xue S, et al. FSHD2- and BAMS-associatedmutations confer opposing effects on SMCHD1
function. J Biol Chem. 2018;293(25):9841-9853. doi:10.1074/jbc.RA118.003104
10. Strafella C, Caputo V, Galota RM, et al. The variability of SMCHD1 gene in FSHD patients: evidence of new
mutations.HumMol Genet. 2019;28(23):3912-3920. doi:10.1093/hmg/ddz239
11. Nguyen K, Broucqsault N, Chaix C, et al. Deciphering the complexity of the 4q and 10q subtelomeres by
molecular combing in healthy individuals and patients with facioscapulohumeral dystrophy. J Med Genet. 2019;56
(9):590-601. doi:10.1136/jmedgenet-2018-105949
12. Dion C, Roche S, Laberthonnière C, et al. SMCHD1 is involved in de novomethylation of the DUX4-encoding
D4Z4macrosatellite. Nucleic Acids Res. 2019;47(6):2822-2839. doi:10.1093/nar/gkz005
13. Padberg GW, Lunt PW, KochM, FardeauM. Diagnostic criteria for facioscapulohumeral muscular dystrophy.
Neuromuscul Disord. 1991;1(4):231-234. doi:10.1016/0960-8966(91)90094-9
14. Wang LH, Tawil R. Facioscapulohumeral dystrophy. Curr Neurol Neurosci Rep. 2016;16(7):66. doi:10.1007/
s11910-016-0667-0
15. Nikolic A, Ricci G, Sera F, et al. Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1-3
D4Z4 reduced alleles: experience of the FSHD Italian National Registry. BMJ Open. 2016;6(1):e007798. doi:10.
1136/bmjopen-2015-007798
16. Statland JM, Donlin-Smith CM, Tapscott SJ, Lemmers RJ, van der Maarel SM, Tawil R. Milder phenotype in
facioscapulohumeral dystrophy with 7-10 residual D4Z4 repeats. Neurology. 2015;85(24):2147-2150. Published
online November 11, 2015. doi:10.1212/WNL.0000000000002217
17. Nguyen K, Puppo F, Roche S, et al. Molecular combing reveals complex 4q35 rearrangements in
facioscapulohumeral dystrophy.HumMutat. 2017;38(10):1432-1441. doi:10.1002/humu.23304
18. Ricci G, Scionti I, Sera F, et al. Large scale genotype-phenotype analyses indicate that novel prognostic tools are
required for families with facioscapulohumeral muscular dystrophy. Brain. 2013;136(Pt 11):3408-3417. doi:10.
1093/brain/awt226
19. van Overveld PG, Lemmers RJ, Deidda G, et al. Interchromosomal repeat array interactions between
chromosomes 4 and 10: a model for subtelomeric plasticity.HumMol Genet. 2000;9(19):2879-2884. doi:10.
1093/hmg/9.19.2879
20. WohlgemuthM, Lemmers RJ, van der Kooi EL, et al. Possible phenotypic dosage effect in patients compound
heterozygous for FSHD-sized 4q35 alleles. Neurology. 2003;61(7):909-913. doi:10.1212/WNL.61.7.909
21. Tawil R, Storvick D, Feasby TE, Weiffenbach B, Griggs RC. Extreme variability of expression in monozygotic
twins with FSHmuscular dystrophy. Neurology. 1993;43(2):345-348. doi:10.1212/WNL.43.2.345
22. Goto K, Nishino I, Hayashi YK. Very low penetrance in 85 Japanese families with facioscapulohumeral muscular
dystrophy 1A. J Med Genet. 2004;41(1):e12. doi:10.1136/jmg.2003.008755
23. Tonini MM, Passos-BuenoMR, Cerqueira A, Matioli SR, Pavanello R, Zatz M. Asymptomatic carriers and gender
differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord. 2004;14(1):33-38. doi:10.
1016/j.nmd.2003.07.001
24. Ricci G, Zatz M, Tupler R. Facioscapulohumeral muscular dystrophy: more complex than it appears. Curr Mol
Med. 2014;14(8):1052-1068. doi:10.2174/1566524014666141010155054
25. van der Kooi AJ, Visser MC, Rosenberg N, et al. Extension of the clinical range of facioscapulohumeral
dystrophy: report of six cases. J Neurol Neurosurg Psychiatry. 2000;69(1):114-116.
26. Pastorello E, CaoM, Trevisan CP. Atypical onset in a series of 122 cases with facioscapulohumeral muscular
dystrophy. Clin Neurol Neurosurg. 2012;114(3):230-234. doi:10.1016/j.clineuro.2011.10.022
27. Krasnianski M, Eger K, Neudecker S, Jakubiczka S, Zierz S. Atypical phenotypes in patients with
facioscapulohumeral muscular dystrophy 4q35 deletion. Arch Neurol. 2003;60(10):1421-1425. doi:10.1001/
archneur.60.10.1421
28. Sakellariou P, Kekou K, Fryssira H, et al. Mutation spectrum and phenotypic manifestation in FSHD Greek
patients. Neuromuscul Disord. 2012;22(4):339-349. doi:10.1016/j.nmd.2011.11.001
29. Tsuji M, Kinoshita M, Imai Y, KawamotoM, Kohara N. Facioscapulohumeral muscular dystrophy presenting
with hypertrophic cardiomyopathy: a case study.Neuromuscul Disord. 2009;19(2):140-142. doi:10.1016/j.nmd.
2008.11.011
30. Felice KJ, Moore SA. Unusual clinical presentations in patients harboring the facioscapulohumeral dystrophy
4q35 deletion.Muscle Nerve. 2001;24(3):352-356. doi:10.1002/1097-4598(200103)24:3<352::AID-MUS1005>3.
0.CO;2-M
JAMANetworkOpen | Neurology Phenotypic Variability Among Patients With D4Z4 Reduced Allele FSHD
JAMA Network Open. 2020;3(5):e204040. doi:10.1001/jamanetworkopen.2020.4040 (Reprinted) May 1, 2020 11/13
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 06/17/2020
31. Wood-Allum C, Brennan P, Hewitt M, Lowe J, Tyfield L, Wills A. Clinical and histopathological heterogeneity in
patients with 4q35 facioscapulohumeral muscular dystrophy (FSHD). Neuropathol Appl Neurobiol. 2004;30(2):
188-191. doi:10.1046/j.0305-1846.2003.00520.x
32. Sugie K, Hayashi YK, Kin T, Goto K, Nishino I, Ueno S. Teaching NeuroImages: hemiatrophy as a clinical
presentation in facioscapulohumeral muscular dystrophy. Neurology. 2009;73(5):e24. doi:10.1212/WNL.
0b013e3181b04af9
33. Zouvelou V, Manta P, Kalfakis N, Evdokimidis I, Vassilopoulos D. Asymptomatic elevation of serum creatine
kinase leading to the diagnosis of 4q35 facioscapulohumeral muscular dystrophy. J Clin Neurosci. 2009;16(9):
1218-1219. doi:10.1016/j.jocn.2008.12.004
34. Reilich P, SchrammN, Schoser B, et al. Facioscapulohumeral muscular dystrophy presenting with unusual
phenotypes and atypical morphological features of vacuolar myopathy. J Neurol. 2010;257(7):1108-1118. doi:10.
1007/s00415-010-5471-1
35. Figueroa JJ, Chapin JE. Isolated facial diplegia and very late-onset myopathy in two siblings: atypical
presentations of facioscapulohumeral dystrophy. J Neurol. 2010;257(3):444-446. doi:10.1007/s00415-009-
5346-5
36. Jordan B, Eger K, Koesling S, Zierz S. Camptocormia phenotype of FSHD: a clinical andMRI study on six
patients. J Neurol. 2011;258(5):866-873. doi:10.1007/s00415-010-5858-z
37. Filosto M, Tonin P, Scarpelli M, et al. Novel mitochondrial tRNA Leu(CUN) transition and D4Z4 partial deletion
in a patient with a facioscapulohumeral phenotype. Neuromuscul Disord. 2008;18(3):204-209. doi:10.1016/j.nmd.
2007.12.005
38. Rudnik-Schöneborn S, Weis J, KressW, Häusler M, Zerres K. Becker’s muscular dystrophy aggravating
facioscapulohumeral muscular dystrophy—double trouble as an explanation for an atypical phenotype.
Neuromuscul Disord. 2008;18(11):881-885. doi:10.1016/j.nmd.2008.06.387
39. Ricci G, Scionti I, Alì G, et al. Rippling muscle disease and facioscapulohumeral dystrophy-like phenotype in a
patient carrying a heterozygous CAV3 T78Mmutation and a D4Z4 partial deletion: further evidence for “double
trouble” overlapping syndromes. Neuromuscul Disord. 2012;22(6):534-540. doi:10.1016/j.nmd.2011.12.001
40. Masciullo M, Iannaccone E, Bianchi ML, et al. Myotonic dystrophy type 1 and de novo FSHDmutation double
trouble: a clinical andmuscle MRI study. Neuromuscul Disord. 2013;23(5):427-431. doi:10.1016/j.nmd.2013.02.002
41. McGonigal A, Thomas AM, Petty RK. Facioscapulohumeral muscular dystrophy andmyasthenia gravis
co-existing in the same patient: a case report. J Neurol. 2002;249(2):219-220. doi:10.1007/PL00007868
42. Daxinger L, Tapscott SJ, van der Maarel SM. Genetic and epigenetic contributors to FSHD. Curr Opin Genet
Dev. 2015;33:56-61. doi:10.1016/j.gde.2015.08.007
43. Lunt PW, Jardine PE, KochMC, et al. Correlation between fragment size at D4F104S1 and age at onset or at
wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-
facioscapulohumeral muscular dystrophy (FSHD).HumMol Genet. 1995;4(5):951-958. doi:10.1093/hmg/4.5.951
44. Tawil R, Forrester J, Griggs RC, et al; The FSH-DY Group. Evidence for anticipation and association of deletion
size with severity in facioscapulohumeral muscular dystrophy. Ann Neurol. 1996;39(6):744-748. doi:10.1002/
ana.410390610
45. Ricci E, Galluzzi G, Deidda G, et al. Progress in themolecular diagnosis of facioscapulohumeral muscular
dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann
Neurol. 1999;45(6):751-757. doi:10.1002/1531-8249(199906)45:6<751::AID-ANA9>3.0.CO;2-M
46. Butz M, KochMC, Müller-Felber W, Lemmers RJ, van der Maarel SM, Schreiber H. Facioscapulohumeral
muscular dystrophy: phenotype-genotype correlation in patients with borderline D4Z4 repeat numbers. J Neurol.
2003;250(8):932-937. doi:10.1007/s00415-003-1116-y
47. Vitelli F, VillanovaM, Malandrini A, et al. Inheritance of a 38-kb fragment in apparently sporadic
facioscapulohumeral muscular dystrophy.Muscle Nerve. 1999;22(10):1437-1441. doi:10.1002/(SICI)1097-4598
(199910)22:10<1437::AID-MUS15>3.0.CO;2-7
48. Ricci G, Ruggiero L, Vercelli L, et al. A novel clinical tool to classify facioscapulohumeral muscular dystrophy
phenotypes. J Neurol. 2016;263(6):1204-1214. doi:10.1007/s00415-016-8123-2
49. Lamperti C, Fabbri G, Vercelli L, et al. A standardized clinical evaluation of patients affected by
facioscapulohumeral muscular dystrophy: the FSHD clinical score.Muscle Nerve. 2010;42(2):213-217. doi:10.1002/
mus.21671
JAMANetworkOpen | Neurology Phenotypic Variability Among Patients With D4Z4 Reduced Allele FSHD
JAMA Network Open. 2020;3(5):e204040. doi:10.1001/jamanetworkopen.2020.4040 (Reprinted) May 1, 2020 12/13
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 06/17/2020
50. Tawil R, Kissel JT, Heatwole C, Pandya S, Gronseth G, Benatar M; Guideline Development, Dissemination, and
Implementation Subcommittee of the American Academy of Neurology; Practice Issues Review Panel of the
American Association of Neuromuscular & Electrodiagnostic Medicine. Evidence-based guideline summary:
evaluation, diagnosis, andmanagement of facioscapulohumeral muscular dystrophy: report of the Guideline
Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the
Practice Issues Review Panel of the American Association of Neuromuscular and Electrodiagnostic Medicine.
Neurology. 2015;85(4):357-364. doi:10.1212/WNL.0000000000001783
51. Mah JK, Feng J, Jacobs MB, et al; Cooperative International Neuromuscular Research Group (CINRG)
Investigators. A multinational study onmotor function in early-onset FSHD.Neurology. 2018;90(15):e1333-e1338.
doi:10.1212/WNL.0000000000005297
52. Wohlgemuth M, Lemmers RJ, Jonker M, et al. A family-based study into penetrance in facioscapulohumeral
muscular dystrophy type 1. Neurology. 2018;91(5):e444-e454. doi:10.1212/WNL.0000000000005915
53. Zatz M, Marie SK, Cerqueira A, Vainzof M, Pavanello RC, Passos-BuenoMR. The facioscapulohumeral muscular
dystrophy (FSHD1) gene affects males more severely andmore frequently than females. Am JMed Genet. 1998;77
(2):155-161. doi:10.1002/(SICI)1096-8628(19980501)77:2<155::AID-AJMG9>3.0.CO;2-R
54. Anderson LJ, Liu H, Garcia JM. Sex differences in muscle wasting. Adv ExpMed Biol. 2017;1043:153-197. doi:
10.1007/978-3-319-70178-3_9
55. Bredella MA. Sex differences in body composition. Adv ExpMed Biol. 2017;1043:9-27. doi:10.1007/978-3-319-
70178-3_2
56. Ruggiero L, Manganelli F, Santoro L. Muscle pain syndromes and fibromyalgia: the role of muscle biopsy. Curr
Opin Support Palliat Care. 2018;12(3):382-387. doi:10.1097/SPC.0000000000000355
SUPPLEMENT.
eTable 1.Distribution of Clinical Categories of Relatives AssociatedWith Clinical Categories of Probands
eTable 2. Clinical Summary of Probands and Relatives by Category
eFigure 1. Population of the Italian Clinical Registry for FSHD
eFigure 2.Distribution of Clinical Phenotypes in Families
JAMANetworkOpen | Neurology Phenotypic Variability Among Patients With D4Z4 Reduced Allele FSHD
JAMA Network Open. 2020;3(5):e204040. doi:10.1001/jamanetworkopen.2020.4040 (Reprinted) May 1, 2020 13/13
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 06/17/2020
